|
2026
|
P/S
|
Providing financial assistance to patients and healthcare providers for prescription drug costs i... |
|
|
P/S
|
Providing financial assistance to patients and healthcare
providers for prescription drug costs ... |
|
2025
|
Invention
|
Rnai agents for dual inhibition of expression of thymic stromal lymphopoietin (tslp) and interleu... |
|
|
Invention
|
Rnai agents for inhibiting expression of interleukin 33 (il33), compositions thereof, and methods... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cardiometabolic diseases. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of
cardiometabolic diseases. |
|
|
Invention
|
Rnai agents for inhibiting expression of synuclein alpha (snca), compositions thereof, and method... |
|
|
Invention
|
Rnai agents for inhibiting expression of mitochondrial amidoxime reducing component 1 (marc1), ph... |
|
|
Invention
|
Rnai agents for inhibiting expression of proprotein convertase subtilisin kexin 9 (pcsk9), pharma... |
|
|
Invention
|
Rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereo... |
|
|
Invention
|
Optimized rnai agents for inhibiting expression of coronavirus (cov) viral genomes, compositions ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cardiometabolic diseases |
|
|
Invention
|
Rnai agents for inhibiting expression of yellow fever virus (yfv) viral genome expression. e.g.in... |
|
|
Invention
|
Cardiomyocyte delivery platforms and methods of use. The present disclosure relates to delivery v... |
|
|
Invention
|
Glucagon-like peptide-1 (glp1) receptor ligands for the delivery of therapeutic agents to cardiom... |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents. in vivoin vivo. The compounds disclosed ... |
|
|
Invention
|
Rnai agents for inhibiting influenza a viral gene expression, compositions thereof, and methods o... |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents to adipose tissue.
Disclosed herein are ... |
|
|
Invention
|
Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions t... |
|
|
Invention
|
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of u... |
|
|
Invention
|
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3).
The pres... |
|
|
Invention
|
Rnai agents for inhibiting expression of myocilin (myoc), compositions thereof, and methods of us... |
|
|
Invention
|
Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical composition... |
|
|
Invention
|
Camera module and vehicle camera.
A camera module comprises: a lens barrel disposed in a front b... |
|
|
Invention
|
Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions ... |
|
|
Invention
|
Rnai agents for dual inhibition of expression of apolipoprotein c-iii (apoc3) and proprotein conv... |
|
|
Invention
|
Methods for the treatment of angptl3-related diseases and disorders.
Described are methods for t... |
|
|
Invention
|
Compositions and methods for inhibition of factor xii gene expression.
RNA interference agents f... |
|
|
Invention
|
Rnai agents for inhibiting expression of androgen receptor (ar), compositions thereof, and method... |
|
|
Invention
|
Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof. The invention provide... |
|
|
Invention
|
Improved linkers and methods for the synthesis of anti-transferrin receptor antibody conjugates. ... |
|
2024
|
Invention
|
Rnai agents for inhibiting expression of activin receptor-like kinase 7 (alk7), compositions ther... |
|
|
Invention
|
Methods and reagents for improved oligonucleotide synthesis. Provided herein are improved reagent... |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents to cns tissue.
Disclosed herein are comp... |
|
|
Invention
|
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin.
The invention re... |
|
|
Invention
|
Organic compositions to treat kras-related diseases.
The present disclosure relates to RNAi agen... |
|
|
Invention
|
Organic compositions to treat beta-catenin-related diseases.
The present disclosure relates to R... |
|
|
Invention
|
Subcutaneous delivery of rnai agents for inhibiting expression of receptor for advanced glycation... |
|
|
Invention
|
Targeting ligands for therapeutic compounds.
Described are novel targeting ligands that may be l... |
|
|
Invention
|
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositi... |
|
|
Invention
|
Oligonucleotide synthesis methods. Disclosed herein are processes or methods for producing oligon... |
|
|
Invention
|
Trialkyne linking agents and methods of use.
Described are improved linking agents that are usef... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cardiometabolic diseases, namely, cardiovascular... |
|
|
Invention
|
Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods... |
|
|
Invention
|
Compositions and methods for inhibiting gene expression of lpa.
RNA interference (RNAi) agents a... |
|
|
Invention
|
Metabolically stabilized carbohydrate targeting ligands for oligonucleotide conjugates |
|
2023
|
Invention
|
Treatment of a non-alcoholic fatty liver disease.
Described are methods of treatment of a non-al... |
|
2022
|
Invention
|
Process for preparation of targeting ligands.
The present application provides synthetic process... |
|
2018
|
P/S
|
Pharmaceutical and medicinal preparations to treat cancer, hepatitis, cardiovascular disease, lun... |
|
|
P/S
|
Pharmaceutical and medicinal preparations to treat
intractable diseases in humans. Development o... |
|
2016
|
P/S
|
Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Ph... |
|
|
P/S
|
Pharmaceutical and medicinal preparations to treat intractable diseases in humans |
